$STEV Reports on Budget Hemp’s Better Than Expected Sales Numbers

Stevia Corp. (OTC PINK: STEV) (“Stevia Corp” or the “Company”), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to provide an update on initial sales of its wholly-owned subsidiary, Real Hemp LLC’s, Budget Hemp™ online store following its launch on August 6, 2015, as well as an update on the status of the Company’s 10-K filing.

The Budget Hemp online store services bulk hemp orders to commercial buyers ranging from dietary supplement and body care manufacturers, hemp infused food and beverage formulators, restaurants and niche bakeries. Budget Hemp™ also offers a full array of co-packing and private label services for hemp products.

Based on an analysis of initial sales trends including unsolicited sales inquiries, and assuming demand remains consistent and there is not an unforeseen economic downturn in the U.S. economy, the Company believes that the Budget Hemp™ online store will be able to generate in excess of $1 million in revenue over the next 12 months.

Orders have been received for a variety of hemp ingredients including organic purified hemp seed oil, shelled hemp seeds, hemp protein and hemp flour with scheduled deliveries being confirmed over the next several months. Average orders are in the $10,000 range.

The Company would also like to highlight two customers of Budget Hemp™. Ultra Oil for Pets, which makes a dietary supplement for pets featuring hemp seed oil and Hillary’s Eat Well, which is developing several hemp infused food products to complement their existing healthy food lines. In each case Budget Hemp™ is proud to be associated with a customer that shares common values and Real Hemp intends to both supply the hemp ingredients, as well as promote the finished retail products on the Realhemp™ online store.

Between the Realhemp™ and Budget Hemp™ online stores, Real Hemp has now received orders from retail and commercial customers covering 30 states.

George Blankenbaker, President of Stevia Corp. commented, “We expect the Budget Hemp™ online store to generate significant revenue as many of its customers are in the product development stage and will increase orders significantly as they move into full production. We are seeing a rapid shift in knowledge, interest and adoption of hemp by the food industry in general as awareness of hemp’s super food nutritional qualities becomes more mainstream and we believe bulk hemp sales will be a growth market for several years providing significant revenue growth opportunity for the Company.”

Separately, the Company appreciates that the investor community is anxious regarding the delayed filing of its annual report. Management continues to be unaware of material factors that will prevent the filing and relisting on the OTCQB marketplace and continues to work diligently with its auditor to finalize the audit. Until the audit is completed, management is not able to make additional comments, but the Company wishes to confirm that management is not aware of any negative material factors. Management also verbally confirmed with OTC Markets that once the Company has filed both its Forms 10-K and 10-Q and is current with its filings, it will be able to update its compliance certificate with the OTC Markets and be relisted immediately on the OTCQB marketplace.

About Stevia Corp. (OTC PINK: STEV)
Stevia Corp. is a farm management company and healthcare company focused on developing highly nutritional, high value products through proprietary plant breeding, excellent agricultural methodologies and innovative post-harvest techniques. Stevia Corp invests in R&D and IP acquisition and manages its own propagation, nursery and plantations as well as provides services to contract growers and other industry growers. Stevia Corp was founded on the principal of implementing socially responsible, sustainable, quality agribusiness solutions to maximize the long-term efficient production of nutritional crops. For additional information please visit:www.steviacorp.us.

About Real Hemp LLC
Real Hemp LLC is a wholly owned subsidiary of Stevia Corp. focused on commercializing the industrial hemp variety of cannabis sativa including its seeds, fiber and cannabinoids.

About the Hemp Industry Sector
Industrial Hemp is a crop that can be grown for food and non-food purposes. As a result of its numerous nutritional benefits, many new food products containing hemp seed and its oil are finding their way into the marketplace, including pasta, tortilla chips, salad dressings, snack products and frozen desserts. Hemp seed contains a complete protein and the seed oil is the richest source of essential fatty acids (Omega-6 and Omega-3) with the perfect ratio of 3:1. Hemp seed oil is also used in nutraceuticals and health care products.

As a fiber source, hemp is undergoing rapid growth as a natural fiber in everything from clothing and textiles to automotive composites. The fiber is also gaining popularity as insulation and other building materials.

The Hemp Industries Association (HIA) estimated that the 2014 retail sales value of hemp food and body care products in the United States was $200 million. When clothing, paper, auto parts, building materials and various other products are included, the HIA estimates that the total retail value of hemp products sold in the U.S. in 2014 to be at least $620 million. Total hemp retail sales in the U.S. have continued to grow steadily and the annual percent growth is estimated by the HIA to have progressed from 7.3% (2011), to 16.5% (2012), to 24% (2013), to 21.2% in 2014.

Industrial Hemp is distinct from marijuana and is defined as the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis.

Although it is legal to import and sell industrial hemp products in the U.S., it is not yet legal to commercially grow industrial hemp in the U.S. The 2013 farm bill was signed into law in February 2014 and contained a hemp amendment, Sec. 7606 Legitimacy of Industrial Hemp Research, which allows states that have already legalized the crop to cultivate hemp within the parameters of state agriculture departments and research institutions.

In January of 2015, The Industrial Hemp Farming Act was introduced in the House and Senate, H.R. 525 and S. 134 respectively. If passed, the bill would remove all federal restrictions on the cultivation of industrial hemp, and remove its classification as a Schedule 1 controlled substance.

About Cannabinoids
There are at least 85 different cannabinoids that have been identified in the cannabis plant. The most notable cannabinoid is tetrahydrocannabinol (THC), which is the primary psychoactive compound in marijuana (a variety of cannabis containing high levels of THC). Cannabidiol (CBD) is another major constituent of the plant and is a primary compound in Industrial Hemp (a variety of cannabis containing less than 0.3% THC on a dry weight basis).

Cannabinoids are a class of diverse chemical compounds that act on cannabinoid receptors. At present there are two known types of cannabinoid receptors, termed CB₁ and CB₂, with mounting evidence of more. The human brain has more cannabinoid receptors than any other G protein-coupled receptor type. CB₁ receptors are found primarily in the brain and CB₂ receptors are predominantly found in the immune system or immune-derived cells. Ligands for these receptor proteins include the endocannabinoids (produced naturally in the body by humans and animals), the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (manufactured artificially).

In October 2003, U.S. patent U.S. Patent 6,630,507 entitled “Cannabinoids as antioxidants and neuroprotectants” was assigned to “The United States Of America As Represented By The Department Of Health And Human Services.” The patent was filed in April 1999 and listed as the inventors: Aidan J. Hampson, Julius Axelrod, and Maurizio Grimaldi, who all held positions at the National Institute of Mental Health (NIMH) in Bethesda, MD, which is part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). The patent mentions cannabidiol’s ability as an antiepileptic, to lower intraocular pressure in the treatment of glaucoma, lack of toxicity or serious side effects in large acute doses, its neuroprotectant properties, its ability to prevent neurotoxicity mediated by NMDA, AMPA, or kainate receptors; its ability to attenuate glutamate toxicity, its ability to protect against cellular damage, its ability to protect brains from ischemic damage, its anxiolytic effect, and its superior antioxidant activity which can be used in the prophylaxis and treatment of oxidation associated diseases.

Oxidative associated diseases include, without limitation, free radical associated diseases, such as ischemia, ischemic reperfusion injury, inflammatory diseases, systemic lupus erythematosus, myocardial ischemia or infarction, cerebrovascular accidents (such as a thromboembolic or hemorrhagic stroke) that can lead to ischemia or an infarct in the brain, operative ischemia, traumatic hemorrhage (for example a hypovolemic stroke that can lead to CNS hypoxia or anoxia), spinal cord trauma, Down’s syndrome, Crohn’s disease, autoimmune diseases (e.g. rheumatoid arthritis or diabetes), cataract formation, uveitis, emphysema, gastric ulcers, oxygen toxicity, neoplasia, undesired cellular apoptosis, radiation sickness, and others. Cannabinoids are believed to be particularly beneficial in the treatment of oxidative associated diseases of the CNS, because of the ability of the cannabinoids to cross the blood brain barrier and exert their antioxidant effects in the brain. It is believed that pharmaceutical composition of cannabinoids can be used for preventing, arresting, or treating neurological damage in Parkinson’s disease, Alzheimer’s disease and HIV dementia; autoimmune neurodegeneration of the type that can occur in encephalitis, and hypoxic or anoxic neuronal damage that can result from apnea, respiratory arrest or cardiac arrest, and anoxia caused by drowning, brain surgery or trauma (such as concussion or spinal cord shock).

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, sales revenue of Budget Hemp™ online store, product delivery schedule, bulk hemp sales as revenue growth opportunity for the Company, timing of completion of the 10-K and 10-Q, timing and relisting on OTCQB marketplace, sales strategy, the potential benefits of the cannabis plant, the commercialization of the cannabis plant, annual retail value of hemp products sold in the U.S., growth of industrial hemp product industry, potential uses of cannabinoids for treatment of various illnesses and diseases, product development and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.